The deal – which is worth up to $905 million with an upfront fee of $90 million – gives BMS full control of BridgeBio's experimental SHP2 inhibitor BBP-398, which is already in a phase 1 trial ...

The researchers combined a newly identified KRAS G12C inhibitor, with a compound that blocks a protein called SHP2, which inhibits cancer cells and can also activate tumor immunity. These two ...

Sanofi has walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as a combination with KRAS inhibitors, including Sanofi’s Mirati ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Erasca (ERAS – Research Report) today. The company’s ...